ACTR-I Antibody (C-5): sc-374523

ACTR-I Antibody (C-5) is a mouse monoclonal IgG2a kappa light chain antibody that detects ACTR-I protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). ACTR-I (C-5) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. ACTR-I protein plays a crucial role in the signaling pathways of the transforming growth factor beta superfamily, which is essential for regulating various cellular processes such as gene expression, cell differentiation, and morphogenesis. ACTR-I protein interacts with type II receptors to form a heteromeric complex that is vital for the activation of downstream signaling cascades. This interaction is particularly important in the brain, where both receptor types are highly expressed, influencing neural development and function. ACTR-I protein′s ability to mediate distinct effects based on ligand concentration underscores its significance in cellular communication and the potential implications in developmental biology and disease states.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

ACTR-I Antibody (C-5) References:

1. A short loop on the ALK-2 and ALK-4 activin receptors regulates signaling specificity but cannot account for all their effects on early Xenopus development.  |  Armes, NA., et al. 1999. J Biol Chem. 274: 7929-35. PMID: 10075688
2. The ActR-I activin receptor protein is expressed in notochord, lens placode and pituitary primordium cells in the mouse embryo.  |  Yoshikawa, SI., et al. 2000. Mech Dev. 91: 439-44. PMID: 10704880
3. The type I BMP receptor ACVR1/ALK2 is required for chondrogenesis during development.  |  Rigueur, D., et al. 2015. J Bone Miner Res. 30: 733-41. PMID: 25413979
4. Involvement of activin a receptor type 1 (ACVR1) in the pathogenesis of primary focal hyperhidrosis.  |  Lin, JB., et al. 2020. Biochem Biophys Res Commun. 528: 299-304. PMID: 32473755
5. Pathogenic ACVR1R206H activation by Activin A-induced receptor clustering and autophosphorylation.  |  Ramachandran, A., et al. 2021. EMBO J. 40: e106317. PMID: 34003511
6. Accumulated Knowledge of Activin Receptor-Like Kinase 2 (ALK2)/Activin A Receptor, Type 1 (ACVR1) as a Target for Human Disorders.  |  Katagiri, T., et al. 2021. Biomedicines. 9: PMID: 34206903
7. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis.  |  Oh, ST., et al. 2023. Blood Adv. 7: 5835-5842. PMID: 37552106
8. Cloning and characterization of a human type II receptor for bone morphogenetic proteins.  |  Rosenzweig, BL., et al. 1995. Proc Natl Acad Sci U S A. 92: 7632-6. PMID: 7644468
9. Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor beta and activin.  |  Cárcamo, J., et al. 1994. Mol Cell Biol. 14: 3810-21. PMID: 8196624
10. Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors.  |  Attisano, L., et al. 1993. Cell. 75: 671-80. PMID: 8242742
11. The ALK-2 and ALK-4 activin receptors transduce distinct mesoderm-inducing signals during early Xenopus development but do not co-operate to establish thresholds.  |  Armes, NA. and Smith, JC. 1997. Development. 124: 3797-804. PMID: 9367435
12. Bone morphogenetic proteins and their receptors: potential functions in the brain.  |  Ebendal, T., et al. 1998. J Neurosci Res. 51: 139-46. PMID: 9469567

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-ACTR-I Antibody (C-5) has 6 citations in a variety of scientific publications.

Primary antibodies like Anti-ACTR-I Antibody (C-5) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

ACTR-I Antibody (C-5) Specifications

Alternate Product Name: ACTR-I

Product Clone Name: C-5

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 21-35

Epitope Target: ACTR-I

Epitope Species: human

Product Reactivity/Detection: ACTR-I

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: equine, canine, bovine and porcine

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 6 citations in various scientific publications

Available Conjugates/Forms for ACTR-I Antibody (C-5): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin